Robert Chen
About
Robert Chen is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics.
According to data from OpenAlex, Robert Chen has authored 81 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Pathology and Forensic Medicine, 60 papers in Oncology and 20 papers in Genetics. Recurrent topics in Robert Chen's work include Lymphoma Diagnosis and Treatment (70 papers), Viral-associated cancers and disorders (22 papers) and Chronic Lymphocytic Leukemia Research (20 papers). Robert Chen is often cited by papers focused on Lymphoma Diagnosis and Treatment (70 papers), Viral-associated cancers and disorders (22 papers) and Chronic Lymphocytic Leukemia Research (20 papers). Robert Chen collaborates with scholars based in United States, France and United Kingdom. Robert Chen's co-authors include Ajay K. Gopal, Scott E. Smith, Craig H. Moskowitz, Joseph D. Rosenblatt, Stephen M. Ansell, Anas Younes, Joseph M. Connors, Andres Forero‐Torres, Emily K. Larsen and Andreas Engert and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Robert Chen
77 papers receiving 4.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Robert Chen United States | 31 | 3.4k | 3.1k | 1.1k | 963 | 939 | 81 | 4.7k | ||
| Radhakrishnan Ramchandren United States | 26 | 3.1k 0.9× | 3.2k 1.0× | 956 0.9× | 977 1.0× | 999 1.1× | 88 | 4.6k | ||
| Michelle A. Fanale United States | 36 | 3.9k 1.1× | 4.1k 1.3× | 1.2k 1.0× | 1.4k 1.4× | 1.2k 1.3× | 252 | 6.4k | ||
| Dana A. Kennedy United States | 24 | 2.8k 0.8× | 3.0k 1.0× | 823 0.7× | 887 0.9× | 761 0.8× | 50 | 4.5k | ||
| Mukesh Chhanabhai Canada | 28 | 2.9k 0.9× | 4.8k 1.5× | 1.2k 1.1× | 1.0k 1.1× | 1.4k 1.5× | 48 | 5.6k | ||
| Mats Jerkeman Sweden | 34 | 2.6k 0.8× | 3.8k 1.2× | 702 0.6× | 612 0.6× | 1.6k 1.8× | 214 | 4.9k | ||
| Alex F. Herrera United States | 28 | 2.5k 0.7× | 2.1k 0.7× | 554 0.5× | 642 0.7× | 587 0.6× | 239 | 3.5k | ||
| Marek Trněný Czechia | 35 | 4.0k 1.2× | 5.0k 1.6× | 1.1k 1.0× | 1.3k 1.4× | 2.4k 2.5× | 326 | 7.0k | ||
| Jason R. Westin United States | 30 | 4.5k 1.3× | 2.4k 0.8× | 616 0.5× | 1.1k 1.2× | 962 1.0× | 224 | 6.0k | ||
| Luigi Rigacci Italy | 28 | 1.6k 0.5× | 3.1k 1.0× | 974 0.9× | 408 0.4× | 809 0.9× | 144 | 4.0k | ||
| Marita Ziepert Germany | 26 | 1.7k 0.5× | 2.7k 0.9× | 944 0.8× | 526 0.5× | 846 0.9× | 101 | 3.4k |
Countries citing papers authored by Robert Chen
Since
Specialization
Citations
This map shows the geographic impact of Robert Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Chen more than expected).
Fields of papers citing papers by Robert Chen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Robert Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Chen. The network helps show where Robert Chen may publish in the future.
Co-authorship network of co-authors of Robert Chen
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Chen. A scholar is included among the top collaborators of Robert Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Chen. Robert Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mei, Matthew, Joycelynne Palmer, Hun Ju Lee, et al.. (2025). Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma. HemaSphere. 9(5). e70126–e70126.
2.
Mei, Matthew, Lu Chen, Sandrine Puverel, et al.. (2024). Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 24(10). 724–731.e1.
3.
Mei, Matthew, Ni‐Chun Tsai, Joycelynne Palmer, et al.. (2024). Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 24(8). 537–542.
4.
Chen, Robert, et al.. (2020). Dihydroartemisinin Prevents Progression and Metastasis of Head and Neck Squamous Cell Carcinoma by Inhibiting Polarization of Macrophages in Tumor Microenvironment. SHILAP Revista de lepidopterología.
5.
Fowler, Nathan, Loretta J. Nastoupil, Sven de Vos, et al.. (2020). The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma. British Journal of Haematology. 189(4). 650–660.
6.
Bartlett, Nancy L., Alex F. Herrera, Eva Domingo‐Doménech, et al.. (2020). A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 136(21). 2401–2409.
7.
Ramchandren, Radhakrishnan, Ranjana H. Advani, Stephen M. Ansell, et al.. (2019). Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research. 25(6). 1718–1726.
8.
Chen, Robert, Alex F. Herrera, Lu Chen, et al.. (2019). Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. Clinical Cancer Research. 26(5). 1034–1044.
9.
Phillips, Tycel, Paul M. Barr, Steven I. Park, et al.. (2018). A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Investigational New Drugs. 37(2). 297–306.
10.
Salhotra, Amandeep, Matthew Mei, Tracey Stiller, et al.. (2018). Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. Biology of Blood and Marrow Transplantation. 25(2). 287–292.
11.
Chen, Robert, Pier Luigi Zinzani, Michelle A. Fanale, et al.. (2017). Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. Journal of Clinical Oncology. 35(19). 2125–2132.
12.
Chen, Robert, Nancy L. Bartlett, Pauline Brice, et al.. (2016). Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. OncoTargets and Therapy. 9. 2027–2027.
13.
Chen, Robert, Edward M. Newman, Young Kim, et al.. (2015). CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin. Molecular Cancer Therapeutics. 14(6). 1376–1384.
14.
Forero‐Torres, Andres, Beata Holkova, Jerome H. Goldschmidt, et al.. (2015). Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 126(26). 2798–2804.
15.
Yasenchak, Christopher A., Andres Forero‐Torres, Rodolfo Bordoni, et al.. (2015). Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study. Blood. 126(23). 587–587.
16.
Chen, Robert, Paul Frankel, Leslie Popplewell, et al.. (2015). A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica. 100(3). 357–362.
17.
Bartlett, Nancy L., Robert Chen, Michelle A. Fanale, et al.. (2014). Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Journal of Hematology & Oncology. 7(1). 24–24.
18.
Mei, Matthew, Sandra H. Thomas, & Robert Chen. (2013). Management of Relapsed or Refractory Hodgkin Lymphoma with Second-Generation Antibody–Drug Conjugates: Focus on Brentuximab Vedotin. BioDrugs. 28(3). 245–251.
19.
Gopal, Ajay K., Nancy L. Bartlett, Andres Forero‐Torres, et al.. (2013). Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leukemia & lymphoma. 55(10). 2328–2334.
20.
Younes, Anas, Ajay K. Gopal, Scott E. Smith, et al.. (2012). Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. Journal of Clinical Oncology. 30(18). 2183–2189.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Radhakrishnan Ramchandren Breakdown of academic impact, for papers by Michelle A. Fanale Breakdown of academic impact, for papers by Dana A. Kennedy Breakdown of academic impact, for papers by Mukesh Chhanabhai Breakdown of academic impact, for papers by Mats Jerkeman Breakdown of academic impact, for papers by Alex F. Herrera Breakdown of academic impact, for papers by Marek Trněný Breakdown of academic impact, for papers by Jason R. Westin Breakdown of academic impact, for papers by Luigi Rigacci Breakdown of academic impact, for papers by Marita Ziepert